On June 24, 2025, JMP Securities analyst Jonathan Wolleben reiterated a "Market Outperform" rating for Skye Bioscience (SKYE, Financial). The analyst maintains a price target of $15.00 USD, which remains unchanged from prior evaluations.
The decision to uphold the price target and rating comes amidst ongoing evaluations of Skye Bioscience's market performance and potential. The $15.00 USD price target reflects confidence in the company's trajectory and potential for growth.
Investors and stakeholders in Skye Bioscience (SKYE, Financial) should take note of this reiteration by JMP Securities as it highlights continued confidence in the company's market position and potential future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Skye Bioscience Inc (SKYE, Financial) is $20.00 with a high estimate of $20.00 and a low estimate of $20.00. The average target implies an upside of 525.00% from the current price of $3.20. More detailed estimate data can be found on the Skye Bioscience Inc (SKYE) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Skye Bioscience Inc's (SKYE, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
